174 related articles for article (PubMed ID: 33186122)
1. Prognostic significance of survival-associated alternative splicing events in gastric cancer.
Zhang S; Hu Z; Lan Y; Long J; Wang Y; Chen X; Xu X; Zeng Z; Ouyang Y
Aging (Albany NY); 2020 Nov; 12(21):21923-21941. PubMed ID: 33186122
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an individual alternative splicing prognostic signature in gastric cancer.
Lou S; Zhang J; Zhai Z; Yin X; Wang Y; Fang T; Xue Y
Aging (Albany NY); 2021 Feb; 13(4):5824-5844. PubMed ID: 33612482
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing acts as an independent prognosticator in ovarian carcinoma.
Ouyang Y; Xia K; Yang X; Zhang S; Wang L; Ren S; Zhou H; Liu Y; Tang F
Sci Rep; 2021 May; 11(1):10413. PubMed ID: 34001978
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
Duan Y; Zhang D
J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of critical alternative splicing events and splicing factors in gastric cancer progression.
Feng H; Jin Z; Liu K; Peng Y; Jiang S; Wang C; Hu J; Shen X; Qiu W; Cheng X; Zhao R
J Cell Mol Med; 2020 Nov; 24(21):12667-12680. PubMed ID: 32939931
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
8. The landscape of alternative splicing reveals novel events associated with tumorigenesis and the immune microenvironment in gastric cancer.
Lou S; Zhang J; Zhai Z; Yin X; Wang Y; Fang T; Xue Y
Aging (Albany NY); 2021 Jan; 13(3):4317-4334. PubMed ID: 33428603
[TBL] [Abstract][Full Text] [Related]
9. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome-wide analysis of alternative mRNA splicing signature in the diagnosis and prognosis of stomach adenocarcinoma.
Shi Y; Chen Z; Gao J; Wu S; Gao H; Feng G
Oncol Rep; 2018 Oct; 40(4):2014-2022. PubMed ID: 30106437
[TBL] [Abstract][Full Text] [Related]
11. Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis.
Lin P; He RQ; Huang ZG; Zhang R; Wu HY; Shi L; Li XJ; Li Q; Chen G; Yang H; He Y
Aging (Albany NY); 2019 Apr; 11(7):2082-2097. PubMed ID: 30986203
[TBL] [Abstract][Full Text] [Related]
12. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
Ma B; Li Y; Ren Y
Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
[TBL] [Abstract][Full Text] [Related]
13. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
[TBL] [Abstract][Full Text] [Related]
14. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
16. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
Liu Y; Jia W; Li J; Zhu H; Yu J
Front Oncol; 2020; 10():587343. PubMed ID: 33117720
[No Abstract] [Full Text] [Related]
17. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.
Shao XY; Dong J; Zhang H; Wu YS; Zheng L
Front Genet; 2020; 11():726. PubMed ID: 32793282
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Endometrial Cancer.
Chen P; He J; Ye H; Jiang S; Li Y; Li X; Wan J
Front Genet; 2020; 11():456. PubMed ID: 32547595
[TBL] [Abstract][Full Text] [Related]
19. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
20. Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer.
Xu L; Pan J; Ding Y; Pan H
Front Genet; 2020; 11():522383. PubMed ID: 33193606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
